Centre for Addiction and Mental Health

Running trials

• Not yet recruiting

  Remote Digital Assessments for Cognitive Disorders

  NCT07883746· Source

• Not yet recruiting

  The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

  NCT07810738· Phase 2· Source

• Enrolling by invitation

  Identifying Biomarkers of Response to Digital Interventions for Mood Disorders

  NCT07783633· Source

• Recruiting

  Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

  NCT07211438· Phase 2· Source

• Recruiting

  Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

  NCT07405606· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Source

• Recruiting

  Theta-Burst Stimulation to Treat Depression

  NCT07033780· Phase 1· Source

• Recruiting

  Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression

  NCT06986460· Phase 3· Source

• Recruiting

  Magnetic Seizure Therapy for Schizophrenia - Trial

  NCT06672588· Source

• Recruiting

  Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

  NCT06512220· Phase 2· Source

• Recruiting

  Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

  NCT06518720· Phase 2· Source

• Recruiting

  Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

  NCT06780917· Source

• Recruiting

  TACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI)

  NCT06783283· Source

• Recruiting

  Predictors of Relapse in Major Depressive Disorder (PERFORM-D)

  NCT06746155· Source

• Recruiting

  Technology-Enabled Collaborative Care for Young Adults With Type 1 Diabetes and Diabetes Distress: A Feasibility Trial

  NCT06804694· Source

• Active, not recruiting

  Psilocybin for Treatment-Resistant Depression in Autism

  NCT06731621· Phase 1· Source

• Recruiting

  Biomarkers to Enhance Early Schizophrenia Treatment

  NCT06969755· Phase 4· Source

• Active, not recruiting

  Effects of Antipsychotics on Brain Insulin Action in Females

  NCT06251635· Source

• Recruiting

  Theta-Burst Stimulation for Bipolar Depression

  NCT06370988· Source

• Recruiting

  rTMS to Improve Motor Function in Autism

  NCT06497920· Source

• Active, not recruiting

  Optimizing CBSST With Executive Function Training for Schizophrenia

  NCT06251193· Source

• Active, not recruiting

  Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography

  NCT06278246· Source

• Active, not recruiting

  Racial Disparities in Antidepressant Treatment After a Psychiatric Consultation

  NCT06799078· Source

• Active, not recruiting

  Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

  NCT06341426· Phase 2· Source

• Recruiting

  Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

  NCT06529744· Source

• Recruiting

  An Innovative Master Platform for Clinical Trials in Mood Disorders

  NCT06408012· Source

• Recruiting

  Cannabidiol for Bipolar Depression (CBD-BD)

  NCT05867849· Phase 3· Source

• Recruiting

  Neuromodulation for Schizophrenia

  NCT05580211· Source

• Recruiting

  Cannabidiol Medication Intervention Trial

  NCT06014424· Phase 2· Source

• Recruiting

  Presynaptic Imaging in Major Depressive Episodes After COVID-19

  NCT06086366· Source

• Active, not recruiting

  Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

  NCT05748990· Source

• Recruiting

  Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability

  NCT05744479· Phase 4· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· Source

• Recruiting

  Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

  NCT05017311· Phase 4· Source

• Recruiting

  Effects of NAC on Symptoms of CHR Patients

  NCT05142735· Source

• Recruiting

  Pragmatic Patient-oriented Extension Study of Dialectical Behavior Therapy Booster Sessions for Youth With and/or at Familial Risk for Bipolar Disorder

  NCT05627492· Source

• Recruiting

  E-field Guided iTBS for Treatment Resistant Depression

  NCT05583747· Source

• Recruiting

  "Extended" (Alternate Day) Antipsychotic Dosing

  NCT04478838· Phase 4· Source

• Active, not recruiting

  Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

  NCT05333003· Source

• Recruiting

  Effectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial

  NCT05142683· Source

• Recruiting

  Left vs. Right Non-Inferiority Trial

  NCT04999553· Source

• Recruiting

  Dialectical Behavior Therapy for Youth With and/or at Familial Risk for Bipolar Disorder

  NCT05153382· Source

• Recruiting

  Three-level Model of DBT-informed Care for Youth With and/or at Familial Risk for Bipolar Disorder (DB3)

  NCT05153369· Source

• Active, not recruiting

  Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia

  NCT05435300· Source

• Active, not recruiting

  Automated Imaging Differentiation of Parkinsonism

  NCT05913687· Source

• Recruiting

  Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression

  NCT04935619· Source

• Recruiting

  Nabilone for Agitation Blinded Intervention Trial

  NCT04516057· Phase 3· Source

• Recruiting

  rTMS for Depression in Young Adults With Autism

  NCT04972136· Source

• Active, not recruiting

  The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia

  NCT04033679· Source

• Active, not recruiting

  Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS

  NCT03846492· Source

Showing 50 of 60.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression16 recruiting
• Bipolar disorder7 recruiting
• Alzheimer disease6 recruiting
• Schizophrenia6 recruiting
• Autism2 recruiting
• Frontotemporal dementia1 recruiting
• Lewy body dementia1 recruiting
• Long COVID and ME/CFS1 recruiting
• Obesity1 recruiting
• Parkinson disease1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Narrative Enhancement and Cognitive Therapy for Self-Stigma in Youth

  NCT06672562· Source

• Terminated

  The Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia

  NCT05957484· Source

• Completed

  Optimizing Mental Health for Young People at Clinical High Risk for Psychosis (CHR)

  NCT05757128· Source

• Completed

  Does Psilocybin Require Psychedelic Effects to Treat Depression?

  NCT05710237· Phase 2· Source

• Completed

  Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

  NCT05473741· Source

• Terminated

  A Remote Electronically Delivered Integrated Care Pathway: A Feasibility Study

  NCT05086120· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Source

• Completed

  "Long COVID-19" on the Human Brain

  NCT05433324· Source

• Completed

  Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression

  NCT05177146· Source

• Completed

  rTMS for Suicidality in Opioid Use Disorder

  NCT04785456· Source

• Completed

  PrEP and Alcohol - Enhancing HIV Pre-Exposure Prophylaxis (PrEP)

  NCT05097430· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

  NCT04846868· Phase 3· Source

• Completed

  Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents

  NCT05571878· Source

• Withdrawn

  Non-Inferiority RCT Comparing Online and On-Site CBT in MDDi

  NCT04825535· Source

• Completed

  A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

  NCT04521478· Phase 2· Source

• Completed

  ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention

  NCT04298450· Source

• Completed

  Minocycline as Adjunctive Treatment for Treatment Resistant Depression

  NCT03947827· Phase 3· Source

• Completed

  RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

  NCT05531591· Phase 4· Source

• Completed

  Reactivity of the Vestibular System to Caloric Vestibular Stimulation in Schizophrenia

  NCT03048370· Source

• Completed

  Efficacy of Convulsive Therapies During Continuation

  NCT03711019· Source

• Completed

  Efficacy of Convulsive Therapies for Bipolar Depression

  NCT03641300· Source

• Completed

  Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression

  NCT03191058· Source

• Completed

  The Effects of tDCS on Illness Awareness in Schizophrenia

  NCT02848885· Source

• Terminated

  Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

  NCT02085265· Phase 2· Source

Trial sites

• Center for Addiction and Mental Health2 trials
• Center for addiction and Mental Health (CAMH)2 trials
• Centre for Addiction and Mental Health62 trials
• Centre for Addiction and Mental Health (CAMH)13 trials
• Centre for Addiction and Mental Health (CAMH & University of Toronto)1 trial
• Centre for Addiction & Mental Health1 trial
• Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health3 trials
• The Center for Addiction and Mental Health1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease87 works · 12 trials
• Schizophrenia82 works · 23 trials
• Depression77 works · 33 trials
• Bipolar disorder63 works · 13 trials